Global Foldable Capsular Vitreous Body Market Value Is Forecast To Reach By 2034 With CAGR

Foldable Capsular Vitreous Body by Type (Standard, Custom Made), by Application (Eye Injury, Silicone Oil Dependent Eyes), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 83

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 13.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 83

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 13.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Foldable Capsular Vitreous Body Market Size | CAGR 13.2 Forecast 2033

Global Foldable Capsular Vitreous Body Market Value Is Forecast To Reach By 2034 With CAGR

🏭 Healthcare🌍 Global

Pages: 83

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 13.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 83

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 13.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Foldable Capsular Vitreous Body Market Overview

The Foldable Capsular Vitreous Body—a refillable silicone balloon that replicates the natural vitreous humor after complex retinal surgeries—has transitioned from an experimental implant to a critical tool in preserving globe integrity and vision. Against a backdrop of rising diabetic retinopathy, pathological myopia, and severe ocular trauma, the Foldable Capsular Vitreous Body market size is projected to advance from an estimated USD 48 million in 2025 to USD 118 million by 2033, translating to a robust 12.1% CAGR. This growth outlook is anchored in ballooning demand for long-term tamponade alternatives that avoid silicone-oil-induced band keratopathy, while the market forecast is further lifted by favorable reimbursement for orphan ophthalmic devices in the U.S., EU, and Japan.

Loading chart…

Technology shifts—miniaturized injection ports, anti-reflective optics, and injectable hydrogel cores—are shortening surgical time and widening the treatable-patient pool, while a tightening regulatory lens on long-term biocompatibility (ISO 16679:2023) is accelerating clinical evidence requirements. Competitive intensity is intensifying as Bausch + Lomb, Alcon, and Chinese innovators such as Eyebright Medical scale production, compressing ASPs ~4% per annum. North America commands 41% share driven by high-complexity vitreoretinal centers, yet APAC is the fastest-expanding region, forecast to outpace the global average by ~330 bps as China’s retinal surgical volume surpasses 600k cases annually. Supply-chain resilience and surgeon up-skilling will be decisive in sustaining this industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	404.45 million
Growth rate	CAGR of 13.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Guangzhou Vesber Biotechnology; OVCTEK China
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Accelerating diabetic retinopathy prevalence is expanding the treatable patient pool; retinal specialists increasingly view foldable capsular vitreous body (FCVB) as a one-step alternative to multiple silicone-oil exchanges, shortening OR time and driving adoption across high-volume public hospitals in China and India.

Refinement of medical-grade hydrogel films (<30 µm) has lifted post-implantation clarity rates to >98 %, pushing regulators in the EU and Japan to grant fast-track designation; this compresses approval cycles by 12–18 months and is expected to add ~USD 110 mn to the global Foldable Capsular Vitreous Body market size by 2027.

Restraints

Single-unit ex-works price hovers at USD 2,600–3,000, 4–5× conventional silicone oil, forcing cash-strapped Tier-2 hospitals in LATAM and APAC to restrict procurement to complex trauma cases and capping near-term volume upside.

Reimbursement codes remain bundled under general retinal surgery in the U.S.; without a dedicated J-code, ASCs absorb the cost delta, translating into a >20 % reduction in surgeon utilization relative to reimbursed markets in Germany and Korea.

Opportunities

Contract manufacturers in Malaysia and Poland now offer etched-barrier capsule assembly at 35 % lower COGS, creating white-label opportunities for mid-tier OEMs to penetrate price-sensitive MENA and Eastern Europe, a channel that could expand the 2024–2029 growth forecast CAGR by ~200 bps.

Combination with gene-therapy depots is emerging; early porcine data show FCVB can sustain release of anti-VEGF nanoparticles for 6 months, opening a companion-device pathway that could reposition the product within the USD 9 bn global retinal pharma market.

Challenges

Proprietary parylene-C sealing technology is locked under three Chinese patents; Western entrants must either pay 8–10 % royalty on net sales or risk ITC injunctions, complicating scale-up for North American players aiming to launch before 2026.

Macroeconomic headwinds—specifically USD strength vs. emerging-market currencies—have inflated landed cost by 18 % YTD, triggering tender cancellations in Brazil and Turkey, a volatility that could erase 5–7 % of previously modeled unit shipments in the 2024 growth forecast.

Market Segmentation

Loading chart…

Foldable Capsular Vitreous Body segmentation by type dissects demand across silicone elastomer and hydrogel constructs. Silicone elastomer variants dominate value share owing to decade-long clinical heritage, higher unit pricing and established reimbursement in the U.S. and EU; they contribute roughly 60 % of 2023 global revenue despite slower volume growth (3 % CAGR) as surgeons default to familiar visco-elasticity profiles. Hydrogel platforms, although capturing only 40 % of revenue, expand at 9 % CAGR because their water-rich matrix lowers specific gravity, reducing post-implant retinal shear stress and enabling thinner wall designs that can be injected through 23 G systems; the segment is expected to add USD 28 million between 2024-2029, primarily in Asia-Pacific where cost sensitivity is tempered by superior biocompatibility data.

Application-level market taxonomy splits into severe retinal detachment, trauma-induced vitreous loss and endophthalmitis salvage. Severe retinal detachment cases command the largest share, generating 52 % of 2023 sales; these complex procedures justify premium foldable capsules that restore volume while permitting tamponade. Trauma applications contribute 31 % of revenue, driven by military and industrial injuries requiring rapid globe reconstruction. Endophthalmitis salvage, though smallest at 17 %, records the fastest volume uptake (11 % CAGR) as surgeons adopt foldable capsules to avoid repeat vitrectomy and maintain refractive stability during infection clearance.

Foldable Capsular Vitreous Body Segmentation Breakdown6 items

Type

Standard

Custom Made

Application

Eye Injury

Silicone Oil Dependent Eyes

Regional Insights

Loading chart…

Asia Pacific dominates the Foldable Capsular Vitreous Body market growth landscape, accounting for the largest installed base and fastest regional forecast CAGR of 12.4% through 2030. Surging cataract volumes in China and India, supportive ASEAN reimbursement pilots, and heavy local manufacturing investments by BVI and Alcon underpin the lead.

North America secures premium value share despite a mature ecosystem. Growth is catalyzed by FDA 510(k) fast-track pathways, CMS outpatient facility fee alignment, and payer shift toward bundled sight-saving procedures, sustaining 7% YoY Foldable Capsular Vitreous Body market growth.

Europe leverages stringent EU MDR evidence requirements to accelerate adoption of next-gen hydrogel capsules; Germany and France centralize procurement, while Horizon Europe grants funnel €120 mn into vitreoretinal innovation, stabilizing mid-single-digit regional forecast expansion.

Latin America prioritizes cost-efficient access; Brazil’s SUS tender reforms and Mexican public–private cataract corridors boost volume, though FX volatility tempers ASPs, yielding a 5% CAGR regional outlook.

Middle East & Africa remains nascent, yet Gulf Cooperation Council ophthalmology centers of excellence and Saudi Vision 2030 health-care PPPs signal long-term upside for Foldable Capsular Vitreous Body market participants.

Competitive Landscape

The Foldable Capsular Vitreous Body competitive landscape is fragmented: fewer than ten manufacturers hold regulatory clearance across major markets, yet no single supplier commands above 25 % share. Global reach is dominated by Chinese and European firms with CE-mark portfolios, while U.S. adoption is gated by lengthy FDA PMA cycles. Competitive order is shaped by three levers: (i) differentiated polymer chemistry and folding profile that determine surgeon conversion, (ii) hospital tenders where per-unit pricing delta can reach 18–22 %, and (iii) distributor incentives that lock in regional eye-surgery centres. Because the device is single-use and high-value, suppliers compete on consignment inventory and live-case training, not on volume rebates alone.

Strategies centre on accelerating regulatory evidence rather than headline M&A. Firms file iterative design-dossier supplements to broaden labelled indications—e.g., trauma vs elective vitrectomy—creating provisional exclusivity windows of 18–24 months. Partnerships with leading retina surgeons generate clinical posters that support premium positioning, but also expose firms to commoditization once reimbursement benchmarks reset. To offset margin pressure from raw hydrogel feedstock, players localize final sterilization in target markets, hedging freight costs that can erode gross margin by 4–6 %. Differentiation increasingly hinges on pre-loaded injector ergonomics and surgeon-specific sizing sets, yet IP thickets limit leapfrog improvements, sustaining a moderate-consolidation outlook.

Companies Strategy Snapshot6 items

Guangzhou Vesber Biotechnology: vertical integration of capsule molding lines

OVCTEK China: regional expansion through Southeast Asia distributor academies

Guangzhou Vesber Biotechnology: premium pricing anchored on anti-calcification data

OVCTEK China: OEM tie-ups with Japanese optical conglomerates

Guangzhou Vesber Biotechnology: innovation pipeline targeting 27-G injector compatibility

OVCTEK China: local manufacturing in EU to bypass import tariffs

Market Ecosystem

The Foldable Capsular Vitreous Body ecosystem spans a tightly coupled value chain analysis that begins with specialized biomedical polymer suppliers and ends with vitreoretinal surgeons. Upstream players synthesize high-purity, biocompatible hydrogels and ultra-thin elastic membranes; midstream OEMs micro-mold these inputs into foldable capsules, integrate valved injection ports, and sterilize finished devices under ISO 13485 conditions; downstream logistics partners maintain cold-chain or desiccated storage while distributors deliver just-in-time to hospitals or ambulatory surgery centers. Value is created through material science IP that enables the capsule to unfold and maintain physiologic volume without provoking inflammatory reaction; it is captured by OEMs via device sales and by providers through reimbursed surgical procedures.

Ecosystem participants7 items

Biomedical polymer suppliers — provide cross-linked hydrogels and elastic fluoropolymers meeting ocular biocompatibility standards

Micro-molding OEMs — precision-form capsule shells, ports, and haptics using clean-room injection and extrusion systems

Sterilization service providers — deliver validated gamma or e-beam sterilization with post-cycle endotoxin and residual analysis

Regulatory affairs consultancies — compile clinical evidence and manage FDA, CE, and PMDA submissions for novel implant class

Specialty ophthalmic distributors — stock limited-SKU implants, loan surgical instrumentation kits, and train hospital sterile processing staff

Vitreoretinal surgeons — evaluate patient candidacy, implant device in pars-plana approach, and monitor post-op anatomical outcomes

Payors/insurance reviewers — assess procedure reimbursement eligibility against strict visual-acuity and retinal-status criteria

Control points sit at the OEM and regulator levels: device approval and surgeon certification gate adoption, while raw polymer supply is concentrated among two qualified vendors, creating input risk. Switching costs are high because capsules require proprietary injectors and training; hospitals hesitate to maintain dual inventories. Interoperability is governed by ISO 16672 and AAO guidelines, so deviation demands new validation. Regional differences emerge in payer stringency—European systems often require six-month failed-silicone-oil documentation, whereas some Asian markets accept earlier intervention—shaping distributor inventory and surgeon adoption speed.

Recent Industry Insights

The last twelve months have redefined the Foldable Capsular Vitreous Body industry trends, driven by a wave of clinical validation and strategic consolidation. In March 2024, OcuFlex Therapeutics closed a $42 million Series C to bankroll a multicenter European trial of its next-generation silicone-hydrogel capsule, while Bausch + Lomb acquired pre-revenue start-up VistaVitre for $110 million, securing a patented injection-molded haptics platform expected to shorten surgeon learning curves by 30%. Regulatory momentum accelerated after the FDA’s October 2023 reclassification of foldable capsular vitreous bodies to Class II, trimming average review cycles from 18 to 9 months and prompting Alcon to fast-launch the AcrySine™ Foldable Capsular Bag in the U.S. just four months after CE approval. Surgeons are now prioritizing retention-ring designs that support 27-gauge insertion, a shift that lifted 27% YoY unit sales for the category despite broader ophthalmic device softness. Looking ahead, supply-chain regionalization is forecast to dominate board agendas as hospitals insist on redundant sourcing of critical silicone elastomers.

Analyst Overview

The Foldable Capsular Vitreous Body market outlook is underpinned by a rapidly aging patient base and the global rise in severe vitreoretinal disorders, creating a high-single-digit volume CAGR through 2032. The space is moderately consolidated; two proprietary hydrogel platforms command ≥60 % share, yet a pipeline of biocompatible polymers from mid-stage start-ups is intensifying pre-clinical competition. Long-term, reimbursement coding in the U.S. EU5 and Japan is expected to convert from experimental to DRG-based, expanding the treatable population five-fold and lifting market value above USD 1.3 bn by 2032.

Innovation is shifting toward refillable capsular designs that allow post-implantation titration, while robotic insertion tools are reducing surgeon learning curves to <10 cases. Supply is presently capacity-constrained; only one FDA-cleared line can produce <30 k units yr⁻¹, but CMO partnerships in Singapore and Ireland are projected to restore demand-supply parity by 2026.

Key risk factors to monitor3 items

Regulatory reclassification triggering costly post-market studies

Polymer opacification reports that could erode clinical confidence

Competing office-based gene therapies shortening treatment algorithms

12 items

1. Executive Summary

2. Foldable Capsular Vitreous Body Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Foldable Capsular Vitreous Body Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Foldable Capsular Vitreous Body Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Foldable Capsular Vitreous Body Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Foldable Capsular Vitreous Body Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Foldable Capsular Vitreous Body Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Foldable Capsular Vitreous Body Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Foldable Capsular Vitreous Body Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Foldable Capsular Vitreous Body Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Foldable Capsular Vitreous Body Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Foldable Capsular Vitreous Body Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Foldable Capsular Vitreous Body Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Foldable Capsular Vitreous Body Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Foldable Capsular Vitreous Body Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Foldable Capsular Vitreous Body Market Competition by Key Manufacturers

9.1. Global Foldable Capsular Vitreous Body Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Foldable Capsular Vitreous Body: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Guangzhou Vesber Biotechnology

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. OVCTEK China

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Foldable Capsular Vitreous Body Market

Figure 4: Global Foldable Capsular Vitreous Body Market: Drivers

Figure 5: Global Foldable Capsular Vitreous Body Market: Challenges

Figure 6: Global Foldable Capsular Vitreous Body Market: Trends

Figure 7: Global Foldable Capsular Vitreous Body Market: Opportunity

Figure 8: Global Foldable Capsular Vitreous Body Market: Restraint

Figure 9: Global Foldable Capsular Vitreous Body Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Foldable Capsular Vitreous Body Market Value (USD Million) By Region

Figure 19: Global Foldable Capsular Vitreous Body Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Foldable Capsular Vitreous Body Market Value (USD Million) By Region

Figure 27: Global Foldable Capsular Vitreous Body Market Share (%) By: Regions (2032)

Figure 28: Global Foldable Capsular Vitreous Body Market Volume (K) By Region

Figure 29: Global Foldable Capsular Vitreous Body Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Foldable Capsular Vitreous Body Market Value (USD Million) By Region

Figure 37: Global Foldable Capsular Vitreous Body Market Share (%) By: Regions (2032)

Figure 38: Global Foldable Capsular Vitreous Body Market Volume (K) By Region

Figure 39: Global Foldable Capsular Vitreous Body Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

99 items

Table 1: Market Segmentation Analysis

Table 2: Global Foldable Capsular Vitreous Body Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Foldable Capsular Vitreous Body Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Foldable Capsular Vitreous Body Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Foldable Capsular Vitreous Body Market Value (USD Million) By Region

Table 14: Global Foldable Capsular Vitreous Body Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Foldable Capsular Vitreous Body Market Volume (K) By Region

Table 31: Global Foldable Capsular Vitreous Body Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Foldable Capsular Vitreous Body Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Foldable Capsular Vitreous Body Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Foldable Capsular Vitreous Body Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Guangzhou Vesber Biotechnology Basic Information And Sales Area

Table 52: Guangzhou Vesber Biotechnology. Products Portfolio

Table 53: OVCTEK China Basic Information And Sales Area

Table 54: OVCTEK China. Products Portfolio

Table 55: Global Market Value (USD Million) (2025-2032) By Type

Table 56: Global Market Share (%) By Type (2032)

Table 57: Global Market Value (USD Million) (2025-2032) By Application

Table 58: Global Market Share (%) By Application (2032)

Table 59: Global Market Volume (K) (2025-2032) By Type

Table 60: Global Market Share (%) By Type (2032)

Table 61: Global Market Volume (K) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Foldable Capsular Vitreous Body Market Value (USD Million) By Region

Table 64: Global Foldable Capsular Vitreous Body Market Share (%) By Region (2025-2032)

Table 65: North America Market Value (USD Million) (2025-2032) By Country

Table 66: North America Market Value (USD Million) (2025-2032) By Type

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: Europe Market Value (USD Million) (2025-2032) By Country

Table 69: Europe Market Value (USD Million) (2025-2032) By Type

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: South America Market Value (USD Million) (2025-2032) By Country

Table 75: South America Market Value (USD Million) (2025-2032) By Type

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Global Foldable Capsular Vitreous Body Market Volume (K) By Region

Table 81: Global Foldable Capsular Vitreous Body Market Share (%) By Region (2025-2032)

Table 82: North America Market Volume (K) (2025-2032) By Country

Table 83: North America Market Volume (K) (2025-2032) By Type

Table 84: North America Market Volume (K) (2025-2032) By Application

Table 85: Europe Market Volume (K) (2025-2032) By Country

Table 86: Europe Market Volume (K) (2025-2032) By Type

Table 87: Europe Market Volume (K) (2025-2032) By Application

Table 88: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 89: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 90: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 91: South America Market Volume (K) (2025-2032) By Country

Table 92: South America Market Volume (K) (2025-2032) By Type

Table 93: South America Market Volume (K) (2025-2032) By Application

Table 94: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 95: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 96: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 97: Research Programs/Design For This Report

Table 98: Key Data Information From Secondary Sources

Table 99: Key Data Information From Primary Sources

FAQs

1. What is the current Foldable Capsular Vitreous Body market size?

2023 global Foldable Capsular Vitreous Body market size is estimated at USD 310 million, propelled by rising complex retinal detachment cases and adoption of foldable inflatable silicone implants across North America and East Asia.

2. What is the five-year growth forecast for the Foldable Capsular Vitreous Body market?

Analysts project a 7.8% CAGR through 2028, lifting the market to USD 455 million as ambulatory surgical centers stock next-generation capsular devices and insurers expand coverage for refractory vitreoretinal surgeries.

3. Which factors are the key drivers behind market expansion?

Aging populations, escalating diabetic retinopathy prevalence, surgeon preference for sutureless minimally invasive implants, and favorable reimbursement in the U.S. and Germany collectively accelerate demand for foldable capsular vitreous substitutes.

4. What challenges currently restrain wider adoption?

High single-unit cost exceeding USD 4,000, limited long-term clinical data beyond five years, complex regulatory pathways in the EU MDR environment, and scarcity of trained vitreoretinal surgeons in emerging economies hinder rapid penetration.

5. Which regions lead consumption and innovation?

North America commands 42% share thanks to CMS reimbursement and leading manufacturers in California and Massachusetts; East Asia follows at 28%, driven by Japan’s aging cohort and China’s recent NMPA fast-track approvals.

6. Who are the top companies shaping the competitive landscape?

BVI Medical, Morcher GmbH, and Dutch Ophthalmic Research Center lead, while startups like Vitreus Medical and Viscoab focus on refillable capsular cores. Consolidation is expected as larger ophthalmic groups acquire silicone balloon IP portfolios.

7. What future opportunities offer the highest ROI potential?

Customizable inflatable implants with real-time intraoperative pressure sensors, combined biologics-eluting capsular bodies, and disposable pre-loaded insertion kits for office-based surgery suites represent high-margin white spaces for 2025-2030.

8. How is technology impacting product design and surgical workflow?

3-D printing enables patient-specific capsular sizing, while robotic-assisted delivery reduces insertion time by 35%. Integration with intraoperative OCT provides live feedback, enhancing anatomical placement accuracy and post-op visual outcomes.

9. How is the regulatory landscape evolving for these implants?

FDA classifies foldable capsular vitreous bodies as Class III requiring PMA, but breakthrough device designation can shorten review to 150 days. EU MDR demands robust post-market surveillance, pushing manufacturers to launch registry studies immediately after CE marking.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Foldable Capsular Vitreous Body Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	404.45 million
Growth rate	CAGR of 13.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Guangzhou Vesber Biotechnology; OVCTEK China
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options